Allogene Therapeutics (ALLO) Interest Coverage Ratio (2018 - 2026)
Allogene Therapeutics (ALLO) posted Interest Coverage Ratio of 0.45 for Q1 2026, up 87.15% sequentially from 3.49 in Q4 2025, and up 90.31% YoY from 0.24 in Q1 2025.
Powered by 
Analysis
Allogene Therapeutics (ALLO) Interest Coverage Ratio (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Interest Coverage Ratio for 9 years, with the latest figure at 0.45 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 90.31% year-over-year to 0.45 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1.85 (up 90.3% YoY) and the FY2025 annual result came in at 16.23, down 2541.71% from the prior year.
- Interest Coverage Ratio grew to 0.45 in Q1 2026 per ALLO's latest filing, from 3.49 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 14.18 in Q4 2023 and troughed at 746.79 in Q4 2024.
- A 5-year average of 50.01 and a median of 2.33 in 2022 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2023 and 2024: Interest Coverage Ratio soared 201.54% in 2023, then sank 5364.71% in 2024.
- Over 5 years, Interest Coverage Ratio stood at 13.97 in 2022, then soared by 201.54% to 14.18 in 2023, then tumbled by 5364.71% to 746.79 in 2024, then soared by 99.53% to 3.49 in 2025, then jumped by 87.15% to 0.45 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 0.45, 3.49, and 1.85 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Allogene Therapeutics | 647.99 Mn | 647.99 Mn | - | -136.79 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -136.79 |
| Mar 31, 2026 | -153.64 |
| Dec 31, 2025 | -135.48 |
| Sep 30, 2025 | -130.53 |
| Jun 30, 2025 | -212.01 |
| Mar 31, 2025 | -434.61 |
| Dec 31, 2024 | -746.79 |
| Sep 30, 2024 | -717.74 |
| Dec 31, 2023 | 29.00 |
| Mar 31, 2023 | -33.76 |
| Mar 31, 2022 | -228.61 |
| Dec 31, 2021 | 1.47 |
| Sep 30, 2021 | -85.45 |
| Jun 30, 2021 | -133.76 |
| Mar 31, 2021 | -102.16 |
| Dec 31, 2020 | -90.55 |
| Sep 30, 2020 | -420.00 |
| Jun 30, 2020 | -404.86 |
| Mar 31, 2020 | -994.53 |
| Dec 31, 2019 | -240.95 |